Search

everythinglearnresearchcommunity

for

Search:↓

The over-the-counter supplement DHEA could make COVID-19 worse, especially in diabetics and people with G6PD deficiency.

Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Early balding at 40 increases prostate cancer risk.

Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.

Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.

Dermatologists should carefully manage hair loss in cancer patients to improve their quality of life.

PCOS may increase the risk of certain cancers.

PCOS is linked to a higher risk of endometrial cancer but not ovarian or breast cancer, and more research is needed on its role in cancer development and treatment effects.

Patients with nonmelanoma skin cancers are most bothered by fear of progression, appearance concerns, and having cancer.

Higher BMI is linked to a lower risk of non-aggressive prostate cancer and a higher risk of aggressive prostate cancer.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Men with baldness at the front and top of their head at age 45 may have a higher risk of aggressive prostate cancer.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

Tamoxifen caused hair loss in a 52-year-old woman.

Removing lymph nodes does not improve survival for advanced ovarian cancer and may cause more complications.

Women who had cancer treatment feel both positive and negative about their bodies.

Repeated use of protein hair conditioner with heat or gamma irradiation can harm skin and hair health in rats.

Long-term use of oral contraceptives, especially starting before age 20, may increase the risk of early-onset breast cancer.

Chemotherapy-induced hair loss significantly affects patients' well-being, and nurses are key in helping them cope, but more research is needed to find effective treatments.

Using finasteride or dutasteride does not increase the risk of male breast cancer.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.

A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.

Older ovarian cancer patients live longer and tolerate weekly chemotherapy better than three-weekly treatments.

A group has developed therapies that show promise for treating cancer and various other conditions.